Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial

被引：24

作者：

Avettand-Fenoel, Veronique ^{[1
,2
]}

Flandre, Philippe ^{[3
,4
]}

Chaix, Marie-Laure ^{[2
]}

Ghosn, Jade ^{[2
,5
]}

Delaugerre, Constance ^{[2
]}

Raffi, Francois ^{[6
]}

NgoVan, Philippe

Cohen-Codar, Isabelle

Delfraissy, Jean-Francois ^{[5
]}

Rouzioux, Christine ^{[2
]}

机构：

[1] Hop Necker Enfants Malad, Virol Lab, CHU Necker Enfants Malad, AP HP, F-75015 Paris, France

[2] Univ Paris 05, EA3620, Paris, France

[3] INSERM, UMR S 943, Paris, France

[4] Univ Paris 06, Paris, France

[5] CHU Kremlin Bicetre, Le Kremlin Bicetre, France

[6] CHU Nantes, Nantes, France

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2010年 / 65卷 / 05期

关键词：

HIV reservoirs; protease inhibitors; antiretroviral-naive patients; ACTIVE ANTIRETROVIRAL THERAPY; DNA; INFECTION; LOAD;

D O I：

10.1093/jac/dkq084

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

To study the impact of protease inhibitor monotherapy on the HIV-1 blood reservoir in 72 antiretroviral-naive patients. This was evaluated for 72 antiretroviral-naive patients included in the on-treatment analysis of the MONARK trial; 46 patients receiving lopinavir/ritonavir monotherapy and 26 patients receiving a triple therapy. HIV-DNA was quantified in whole blood, using real-time PCR. The decrease in HIV-DNA after 48 weeks of lopinavir/ritonavir monotherapy was similar to the decrease observed with triple therapy including lopinavir/ritonavir (-0.77 versus -0.69 log copies/10(6) leucocytes, respectively; P = 0.91). The HIV-DNA decrease was also similar in patients with a virological response in both arms (-0.69 versus -0.69 log copies/10(6) leucocytes, respectively). Interestingly, non-responders had a significantly higher baseline HIV-DNA load than responders in the monotherapy arm; 3.16 versus 2.86 log copies/10(6) leucocytes, respectively (P = 0.05). The MONARK data indicate that a lopinavir/ritonavir monotherapy regimen is potent against HIV blood reservoirs in antiretroviral-naive patients after 1 year of treatment, in comparison with a standard-of-care highly active antiretroviral therapy. This impact should be evaluated with other boosted protease inhibitor monotherapies.

引用

页码：1005 / 1007

页数：3

共 10 条

[1] HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors [J].

Avettand-Fenoel, Veronique ;

Prazuck, Thierry ;

Hocqueloux, Laurent ;

Melard, Adeline ;

Michau, Christophe ;

Kerdraon, Remy ;

Agoute, Eric ;

Rouzioux, Christine .

AIDS, 2008, 22 (14) :1880-1882

[2] LTR Real-Time PCR for HIV-1 DNA Quantitation in Blood Cells for Early Diagnosis in Infants Born to Seropositive Mothers Treated in HAART Area (ANRS CO 01) [J].

Avettand-Fenol, Veronique ;

Chaix, Marie-Laure ;

Blanche, Stephane ;

Burgard, Marianne ;

Floch, Corinne ;

Toure, Kadidia ;

Allemon, Marie-Christine ;

Warszawski, Josiane ;

Rouzioux, Christine .

JOURNAL OF MEDICAL VIROLOGY, 2009, 81 (02) :217-223

[3] Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients [J].

Delfraissy, Jean-Fran Ois ;

Flandre, Philippe ;

Delaugerre, Constance ;

Ghosn, Jade ;

Horban, Andrzej ;

Girard, Pierre-Marie ;

Norton, Michael ;

Rouzioux, Christine ;

Taburet, Anne-Marie ;

Cohen-Codar, Isabelle ;

Van, Philippe Ngo ;

Chauvin, Jean-Pierre .

AIDS, 2008, 22 (03) :385-393

[4] Long-term (96-week) follow-up of antiretroviral-naive HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial [J].

Ghosn, J. ;

Flandre, P. ;

Cohen-Codar, I. ;

Girard, P-M ;

Chaix, M-L ;

Raffi, F. ;

Dellamonica, P. ;

NgoVan, P. ;

Norton, M. ;

Delfraissy, J-F .

HIV MEDICINE, 2010, 11 (02) :137-142

[5] Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy [J].

Hatzakis, AE ;

Touloumi, G ;

Pantazis, N ;

Anastassopoulou, CG ;

Katsarou, O ;

Karafoulidou, A ;

Goedert, JJ ;

Kostrikis, LG .

AIDS, 2004, 18 (17) :2261-2267

[6] Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years [J].

Havlir, DV ;

Strain, MC ;

Clerici, M ;

Ignacio, C ;

Trabattoni, D ;

Ferrante, P ;

Wong, JK .

JOURNAL OF VIROLOGY, 2003, 77 (20) :11212-11219

[7] Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005 [J].

Hoen, Bruno ;

Cooper, David A. ;

Lampe, Fiona C. ;

Perrin, Luc ;

Clumeck, Nathan ;

Phillips, Andrew N. ;

Goh, Li-Ean ;

Lindback, Stefan ;

Sereni, Daniel ;

Gazzard, Brian ;

Montaner, Julio ;

Stellbrink, Hans-Jurgen ;

Lazzarin, Adriano ;

Ponscarme, Diane ;

Staszewski, Shlomo ;

Mathiesen, Lars ;

Smith, Don ;

Finlayson, Robert ;

Weber, Rainer ;

Wegmann, Laurence ;

Janossy, George ;

Kinloch-de Loes, Sabine .

CLINICAL INFECTIOUS DISEASES, 2007, 45 (03) :381-390

[8]

Morand-Doubert L, 2005, JAIDS-J ACQ IMM DEF, V38, P268

[9] Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy [J].

Ngo-Giang-Huong, N ;

Deveau, C ;

Da Silva, I ;

Pellegrin, I ;

Venet, A ;

Harzic, M ;

Sinet, M ;

Delfraissy, JF ;

Meyer, L ;

Goujard, C ;

Rouzioux, C .

AIDS, 2001, 15 (06) :665-673

[10] Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level [J].

Viard, JP ;

Burgard, M ;

Hubert, JB ;

Aaron, L ;

Rabian, C ;

Pertuiset, N ;

Lourenço, M ;

Rothschild, C ;

Rouzioux, C .

AIDS, 2004, 18 (01) :45-49

← 1 →